Biotech entity
All 1 tracked stories fall under one category: funding. Prometheus is most often covered alongside BlackRock, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Prometheus, all published on June 12, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: funding. Prometheus is most often covered alongside BlackRock, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Prometheus, all published on June 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Prometheus. Shared-story counts are live from our verified record — not editorial picks.
Prometheus's $12B raise envisions an artificial general engineer that can design drug compounds autonomously, potentially cutting years from pharmaceutical R&D. The startup's biotech roots via co-founder Vik Bajaj of Verily add credibility.
Source: TechCrunch · Marina Temkin (us)
Prometheus is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
